Skip to main content

Nacalai to Distribute Techulon Transfection Reagents

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nacalai USA today said that it has signed an agreement to distribute Techulon's Glycofect Transfection Reagent platform products in Japan.

The reagents are designed to be particularly effective in primary cells of therapeutic interest, said Nacalai. In addition, the San Diego-based firm said that the Glycofect family of reagents has a unique biodegradable composition that provides for efficacious delivery with very low toxicity in key cell types.

Financial and other terms of the agreement were not disclosed.

Nacalai USA is a subsidiary of Nacalai Tesque, a Kyoto, Japan-based manufacturer and distributor of research products.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.